Latest Humanized antibody Stories
MORRIS PLAINS, N.J., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L.
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data on SGN-70 at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco, California.
BERKELEY, Calif., Oct. 25, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd.
Immunomedics, a biopharmaceutical company, has received a new US patent that covers the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on B-lymphocytes, leukemias, and lymphomas.
MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S.
DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc.
4-Antibody AG today announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschaeftsfuehrer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence. Previously Dr.
BERKELEY, Calif., Aug. 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its results for the quarter ended June 30, 2008.
CAMBRIDGE, Mass., Aug.
ImmunoCellular Therapeutics, a biotechnology company, has signed a research agreement with UK-based biotechnology company Antitope for the humanization of IMUC's monoclonal antibodies.
- Growing in low tufty patches.